TABLE 1.
Relationship between clinical factors and LATS2 expression in ESCC.
| Characteristic | Level | Low expression of LATS2 | High expression of LATS2 | p |
|---|---|---|---|---|
| N | 81 | 81 | ||
| T stage, n (%) | T1 | 15 (20.5%) | 12 (16.7%) | 0.268 |
| T2 | 19 (26%) | 18 (25%) | ||
| T3 | 39 (53.4%) | 38 (52.8%) | ||
| T4 | 0 (0%) | 4 (5.6%) | ||
| N stage, n (%) | N0 | 36 (49.3%) | 30 (42.3%) | 0.701 |
| N1 | 30 (41.1%) | 33 (46.5%) | ||
| N2 | 5 (6.8%) | 4 (5.6%) | ||
| N3 | 2 (2.7%) | 4 (5.6%) | ||
| M stage, n (%) | M0 | 61 (93.8%) | 60 (93.8%) | 1.000 |
| M1 | 4 (6.2%) | 4 (6.2%) | ||
| Pathologic stage, n (%) | Stage I | 9 (12.5%) | 7 (10%) | 0.599 |
| Stage II | 38 (52.8%) | 31 (44.3%) | ||
| Stage III | 21 (29.2%) | 28 (40%) | ||
| Stage IV | 4 (5.6%) | 4 (5.7%) | ||
| Radiation therapy, n (%) | No | 52 (70.3%) | 55 (78.6%) | 0.343 |
| Yes | 22 (29.7%) | 15 (21.4%) | ||
| Primary therapy outcome, n (%) | PD | 5 (9.4%) | 5 (12.2%) | 0.836 |
| SD | 3 (5.7%) | 4 (9.8%) | ||
| PR | 2 (3.8%) | 1 (2.4%) | ||
| CR | 43 (81.1%) | 31 (75.6%) | ||
| Gender, n (%) | Female | 10 (12.3%) | 13 (16%) | 0.653 |
| Male | 71 (87.7%) | 68 (84%) | ||
| Race, n (%) | Asian | 22 (28.9%) | 16 (23.5%) | 0.035 |
| Black or African American | 6 (7.9%) | 0 (0%) | ||
| White | 48 (63.2%) | 52 (76.5%) | ||
| Age, n (%) | ≤60 | 41 (50.6%) | 42 (51.9%) | 1.000 |
| >60 | 40 (49.4%) | 39 (48.1%) | ||
| BMI, n (%) | ≤25 | 44 (56.4%) | 40 (53.3%) | 0.826 |
| >25 | 34 (43.6%) | 35 (46.7%) | ||
| Histological type, n (%) | Adenocarcinoma | 26 (32.1%) | 54 (66.7%) | <0.001 |
| Squamous cell carcinoma | 55 (67.9%) | 27 (33.3%) | ||
| Histologic grade, n (%) | G1 | 11 (16.7%) | 5 (8.3%) | 0.346 |
| G2 | 34 (51.5%) | 32 (53.3%) | ||
| G3 | 21 (31.8%) | 23 (38.3%) | ||
| Smoker, n (%) | No | 25 (34.2%) | 22 (31%) | 0.811 |
| Yes | 48 (65.8%) | 49 (69%) | ||
| Alcohol history, n (%) | No | 19 (24.4%) | 27 (33.3%) | 0.283 |
| Yes | 59 (75.6%) | 54 (66.7%) | ||
| Barrett’s esophagus, n (%) | No | 52 (82.5%) | 54 (78.3%) | 0.690 |
| Yes | 11 (17.5%) | 15 (21.7%) | ||
| Tumor central location, n (%) | Distal | 51 (63.7%) | 62 (76.5%) | 0.196 |
| Mid | 25 (31.2%) | 17 (21%) | ||
| Proximal | 4 (5%) | 2 (2.5%) | ||
| Age, median (IQR) | 60 (54, 70) | 60 (53, 75) | 0.519 |